SEC Form 4 · accession 0001209191-18-061100
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dominic Piscitelli
Officer — Chief Financial Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 4, 2018 · 9:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 3, 2018 | M | 37,000 | $11.34 | A | 37,000 | D | |
| Common StockF2 | Dec 3, 2018 | S | 3,554 | $70.336 | D | 33,446 | D | |
| Common StockF3 | Dec 3, 2018 | S | 18,604 | $71.332 | D | 14,842 | D | |
| Common StockF4 | Dec 3, 2018 | S | 4,820 | $72.2432 | D | 10,022 | D | |
| Common StockF5 | Dec 3, 2018 | S | 2,298 | $73.1761 | D | 7,724 | D | |
| Common StockF6 | Dec 3, 2018 | S | 6,624 | $74.33 | D | 1,100 | D | |
| Common StockF7 | Dec 3, 2018 | S | 1,100 | $75.8091 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F9,F8 | $11.34 | Dec 3, 2018 | M | 37,000 | D | — | Jan 7, 2027 | Common Stock | 37,000 | 133,241 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.90 to $70.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.90 to $71.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.91 to $72.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.93 to $73.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.00 to $74.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.44 to $76.26 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 9, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F9In addition to the remaining options to purchase 133,241 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 98,000 shares of common stock, which options vest according to their terms.
Remarks
Exhibit List - Exhibit 24.1 - Power of Attorney